Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a compendium of scientific articles submitted to a Special Issue of International Journal of Molecular Sciences, fostered by MDPI and curated by Dr. Annamaria Sandomenico and Dr. Menotti Ruvo from the Institute of Biostructure and Bioimaging of the National Research Council. All articles underwent a rigorous peer review and were selected to highlight the properties that make monoclonal antibodies and their functional fragments some of the most useful and versatile assets in therapy and diagnosis.

Technology: general issues --- porcine deltacoronavirus --- nucleocapsid --- monoclonal antibodies --- neurodegenerative disorders --- affibody molecules --- blood–brain barrier --- receptor-mediated transcytosis --- transferrin receptor --- AL amyloidosis --- CD38 --- anti-CD38 MoAb --- Daratumumab --- Isatuximab --- myeloma --- BCMA --- bispecific T-cell engager --- antibody-drug conjugates --- chimeric antigen receptor T-cells --- belantamab mafodotin --- idecabtagene vicleucel --- JNJ-68284528 --- Mabs --- Antibody-Drug Conjugate --- cancer therapy --- drug targeting --- payload --- cross-linking --- antibody fragment --- Fab --- scFv --- E. coli --- YKL-40 --- CHI3L1 --- monoclonal antibody --- phage display --- lung metastasis --- prostate-specific membrane antigen --- in vivo imaging --- prostate cancer --- glutamate carboxypeptidase II --- NAALADase --- immunization --- antibody --- protocol --- guinea pig --- cDNA --- chimeric antigen receptor (CAR T) --- universal CAR T --- modular CAR T --- universal immune receptor --- CAR adaptor --- adoptive immunotherapy --- split CAR --- bispecific --- polyspecificity --- pharmacokinetics --- solubility --- aggregation --- viscosity --- developability --- stability --- affinity --- specificity --- protein engineering --- self-association --- non-specific binding --- immunogenicity --- antibody fragments --- single chain --- amyloid --- oligomer --- neurotoxicity --- NUsc1

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Medicine --- Clinical & internal medicine --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Medicine --- Clinical & internal medicine --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell–cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death --- n/a --- cell-cell contact